![Siemens Healthineers announces two new combination tests for both SARS-CoV-2 and other seasonal respiratory pathogens Siemens Healthineers announces two new combination tests for both SARS-CoV-2 and other seasonal respiratory pathogens](https://corporate.webassets.siemens-healthineers.com/355c9b1a69c8d858/a836cc72dedb/v/7bd2803aa3e5/siemens-healthineers-pressCLINITEST_RapidCOVID19AgTest_BoxCass.jpg)
Siemens Healthineers announces two new combination tests for both SARS-CoV-2 and other seasonal respiratory pathogens
![Frontiers | Saline nasal irrigation and gargling in COVID-19: a multidisciplinary review of effects on viral load, mucosal dynamics, and patient outcomes Frontiers | Saline nasal irrigation and gargling in COVID-19: a multidisciplinary review of effects on viral load, mucosal dynamics, and patient outcomes](https://www.frontiersin.org/files/Articles/1161881/fpubh-11-1161881-HTML/image_m/fpubh-11-1161881-g001.jpg)
Frontiers | Saline nasal irrigation and gargling in COVID-19: a multidisciplinary review of effects on viral load, mucosal dynamics, and patient outcomes
![Rapid, adaptable and sensitive Cas13-based COVID-19 diagnostics using ADESSO | Nature Communications Rapid, adaptable and sensitive Cas13-based COVID-19 diagnostics using ADESSO | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-30862-y/MediaObjects/41467_2022_30862_Fig1_HTML.png)
Rapid, adaptable and sensitive Cas13-based COVID-19 diagnostics using ADESSO | Nature Communications
![Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/ddad2030-b355-4c6d-9487-4b9d1e28e855/gr1.jpg)
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases
![Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study - The Lancet Microbe Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study - The Lancet Microbe](https://www.thelancet.com/cms/attachment/3954547e-c65e-47d3-9700-8e615463a34b/gr1_lrg.jpg)